In Brief: FDA reform update
This article was originally published in The Gray Sheet
Executive Summary
FDA reform update: House Republican FDA reform package has 159 cosponsors from "Republicans and Democrats across the political spectrum," Rep. Jim Greenwood (R-Penn.), the floor manager for the package, says in a special order on the House floor May 29. The Commerce Committee plans to release an amended version of the reform package one week prior to mark-up, which is slated to begin in mid-June...
You may also be interested in...
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.